DexCom (NASDAQ:DXCM) had its price objective boosted by investment analysts at UBS Group from $140.00 to $160.00 in a note issued to investors on Thursday, BenzingaRatingsTable reports. The brokerage currently has a “neutral” rating on the medical device company’s stock. UBS Group’s price objective would suggest a potential upside of 10.95% from the company’s previous close.
A number of other brokerages have also recently weighed in on DXCM. BTIG Research reaffirmed a “hold” rating on shares of DexCom in a research report on Thursday. Piper Jaffray Companies boosted their price target on DexCom from $173.00 to $182.00 and gave the stock a “positive” rating in a research report on Wednesday. Raymond James boosted their price target on DexCom from $150.00 to $172.00 and gave the stock an “outperform” rating in a research report on Thursday. BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a research report on Tuesday, July 23rd. Finally, Canaccord Genuity boosted their price target on DexCom from $160.00 to $185.00 and gave the stock a “buy” rating in a research report on Thursday. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $163.71.
DXCM traded down $4.11 during trading on Thursday, reaching $144.21. 1,234,833 shares of the stock traded hands, compared to its average volume of 687,584. The stock has a market cap of $13.13 billion, a PE ratio of 480.70 and a beta of 0.80. DexCom has a fifty-two week low of $105.05 and a fifty-two week high of $161.30. The company has a debt-to-equity ratio of 1.57, a quick ratio of 6.75 and a current ratio of 7.18. The firm’s 50-day moving average price is $149.93.
In other news, EVP Richard Doubleday sold 2,016 shares of DexCom stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $153.56, for a total value of $309,576.96. Following the transaction, the executive vice president now directly owns 72,570 shares in the company, valued at $11,143,849.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Patrick Michael Murphy sold 400 shares of the business’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $116.92, for a total value of $46,768.00. The disclosure for this sale can be found here. Insiders sold 63,065 shares of company stock worth $8,207,313 over the last quarter. 1.80% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP lifted its position in shares of DexCom by 2.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 164,763 shares of the medical device company’s stock valued at $19,738,000 after buying an additional 3,468 shares in the last quarter. Stifel Financial Corp lifted its position in shares of DexCom by 88.0% during the 4th quarter. Stifel Financial Corp now owns 3,614 shares of the medical device company’s stock valued at $435,000 after buying an additional 1,692 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of DexCom by 17.2% during the 4th quarter. Geode Capital Management LLC now owns 1,042,131 shares of the medical device company’s stock valued at $124,776,000 after buying an additional 152,781 shares in the last quarter. MML Investors Services LLC purchased a new position in shares of DexCom during the 4th quarter valued at approximately $360,000. Finally, Advisory Services Network LLC lifted its position in shares of DexCom by 155.5% during the 4th quarter. Advisory Services Network LLC now owns 1,482 shares of the medical device company’s stock valued at $178,000 after buying an additional 902 shares in the last quarter. Hedge funds and other institutional investors own 96.27% of the company’s stock.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: How is diluted EPS different from basic EPS?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.